Curated News
By: NewsRamp Editorial Staff
June 02, 2026
Quantum BioPharma Hires IR Agency to Boost Investor Outreach
TLDR
- Quantum BioPharma's $250k deal with Stocks.news boosts visibility, potentially driving investor interest and stock value.
- Quantum BioPharma hired IR Agency LLC for six months to provide media distribution, community building, and lead generation for $250,000.
- Quantum BioPharma advances treatments for neurodegenerative diseases and alcohol misuse, aiming to improve patient quality of life.
- UNBUZZD(TM) royalty payments to Quantum could reach $250 million, then drop to 3% in perpetuity, creating long-term revenue.
Impact - Why it Matters
This news matters because it signals Quantum BioPharma's proactive strategy to enhance its market visibility and attract investor attention as it advances promising therapies for multiple sclerosis and alcohol misuse. The investor relations agreement with Stocks.news could lead to increased awareness among potential investors, potentially impacting the company's stock liquidity and valuation. For patients and the medical community, greater visibility may accelerate the development and eventual availability of treatments like Lucid-MS, which targets the root cause of MS by preventing and reversing myelin degradation. The royalty stream from UNBUZZD also provides a potential revenue source, strengthening Quantum's financial position to fund further research.
Summary
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company advancing innovative therapies for neurodegenerative and metabolic disorders, has announced a strategic investor relations and consulting services agreement with Stocks.news through IR Agency LLC, effective June 8, 2026. Under the six-month contract, IR Agency LLC will provide services including company profile creation, media distribution, digital community development, news marketing, and lead generation campaigns for a fee of US$250,000. Quantum confirmed that IR Agency LLC is an arm's-length entity with no direct or indirect equity interest in its securities, ensuring independence in the engagement. This move aims to enhance Quantum's visibility and investor outreach as it continues to develop its pipeline of drug candidates targeting multiple sclerosis, alcohol misuse, and other challenging conditions.
Quantum BioPharma is dedicated to building a portfolio of innovative biotech solutions, with lead compound Lucid-MS, developed by its wholly owned subsidiary Lucid Psycheceuticals Inc. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models, addressing the underlying mechanism of multiple sclerosis. Additionally, Quantum invented UNBUZZD(TM) and spun out its OTC version to Unbuzzd Wellness Inc., retaining a 19.84% ownership stake (as of March 31, 2026) and a royalty agreement: 7% of sales until payments total $250 million, then 3% in perpetuity. Quantum also retains 100% rights to develop pharmaceutical formulations. The company's newsroom provides ongoing updates at https://ibn.fm/QNTM, and the full press release is available at https://ibn.fm/iBZrw.
This announcement underscores Quantum's commitment to leveraging strategic communications to advance its mission. The agreement with Stocks.news through IR Agency LLC is part of a broader effort to increase awareness among investors and stakeholders. As Quantum continues to progress its drug candidates through development, the partnership is expected to support its goal of bringing transformative therapies to market, potentially impacting patients suffering from neurodegenerative diseases and alcohol misuse disorders. The company's innovative approach, including its work on Lucid-MS and the UNBUZZD platform, positions it as a notable player in the biopharmaceutical landscape.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Quantum BioPharma Hires IR Agency to Boost Investor Outreach
